International Clinical Trial: Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07830329) titled 'Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity' on Sept. 15.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Regeneron Pharmaceuticals

Condition: Hidradenitis Suppurativa

Intervention: Drug: Olatorepatide

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: October 30, 2026

Target Sample Size: 300

To ...